BioXcel Therapeutics announced it has approximately $35 million in cash following the successful raise of $14 million in gross proceeds from an equity financing that closed on March 4, 2025. This strengthened cash position is intended to support the continued advancement of the company’s pivotal Phase 3 SERENITY At-Home trial.
The SERENITY At-Home trial is evaluating the safety of BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting. Patient enrollment is ongoing, with topline data results expected in the second half of 2025.
The anticipated data readout is intended to support a potential supplemental new drug application (sNDA) submission to expand the label for IGALMI in the at-home setting, addressing a significant unmet medical need for millions of patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.